<DOC>
	<DOC>NCT01517373</DOC>
	<brief_summary>This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin</brief_summary>
	<brief_title>Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 1870 yrs, male and females, with T2DM, on metformin alone or in combination with 1 other oral agent Subjects with recent cardiovascular events, those with evidence of diabetic complications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>T2DM</keyword>
	<keyword>PF-04937319</keyword>
	<keyword>Phase 2</keyword>
</DOC>